Publications by authors named "A Caneva"
(AAV)-mediated episomal gene replacement therapy for monogenic liver disorders is currently limited in pediatric settings due to the loss of vector DNA, associated with hepatocyte duplication during liver growth. Genome editing is a promising strategy leading to a permanent and specific genome modification that is transmitted to daughter cells upon proliferation. Using genome targeting, we previously rescued neonatal lethality in mice with Crigler-Najjar syndrome.
View Article and Find Full Text PDFRationale And Objectives: Our multicentric study analysed clinical, radiologic and pathologic features in patients with atypical ductal hyperplasia (ADH) diagnosed with vacuum-assisted biopsy (VAB), to identify factors associated with the risk of upgrade, to develop a scoring system to support decision making.
Materials And Methods: Patients with ADH on VAB under stereotactic/tomosynthesis guidance (2012-2022) were eligible. Inclusion criteria were availability of surgical histopathological examination of the entire lesion or radiologic follow-up (FUP) ≥ 24 months.
Objective: to determine the positive predictive value (PPV) of tomosynthesis (DBT)-detected architectural distortions (ADs) and evaluate correlations between AD's imaging characteristics and histopathologic outcomes.
Methods: biopsies performed between 2019 and 2021 on ADs were included. Images were interpreted by dedicated breast imaging radiologists.
Article Synopsis
- - The study investigates using integrative gene therapy to treat hemophilia B in mouse models, showing that AAV8 vectors can effectively deliver the human coagulation factor IX (hFIX) gene and maintain elevated hFIX levels for at least 10 months in neonatal mice.
- - A single injection not only led to stable hFIX expression but also restored normal clotting capabilities in young FIX knockout mice, indicating a successful correction of the disease phenotype.
- - While the same approach in adult mice resulted in detectable hFIX levels, it was insufficient to meaningfully reduce bleeding risk, highlighting differences in gene therapy efficacy based on the age of the subjects.
Objectives: To compare the conspicuity of lobular breast cancers at digital breast tomosynthesis (DBT) versus synthesized 2D mammography (synt2D).
Materials And Methods: Seventy-six women (mean age 61.2 years, range 50-74 years) submitted to biopsy in our institution, from 2019 to 2021, with proven invasive lobular breast cancer (ILC) were enrolled in this retrospective study.